Carson Wealth (CWM LLC)’s 4D Molecular Therapeutics FDMT Stock Holding History

Carson Wealth (CWM LLC)’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$44.7K	Sell	4,806 -172	-3%	-$1.5K	﹤0.01%	3897
2025 Q4	$37K	Buy	4,978 +56	+1%	+$568	﹤0.01%	3814
2025 Q3	$43K	Buy	4,922 +774	+19%	+$4.63K	﹤0.01%	3643
2025 Q2	$15K	Buy	4,148 +2,281	+122%	+$8.02K	﹤0.01%	4078
2025 Q1	$6K	Buy	1,867 +1,136	+155%	+$5.35K	﹤0.01%	4358
2024 Q4	$4K	Buy	731 +719	+5,992%	+$5.64K	﹤0.01%	4301
2024 Q3	$0	Buy	12 +6	+100%	+$100	﹤0.01%	4911
2024 Q2	$0	Buy	+6	New	+$151	﹤0.01%	4688
2022 Q2	–	Sell	-47	Closed	-$1K	–	3881
2022 Q1	$1K	Buy	+47	New	+$738	﹤0.01%	3339

Other funds holding FDMT

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Carson Wealth (CWM LLC)'s FDMT Position: Q1 2026 in Review

Carson Wealth (CWM LLC) reduced its 4D Molecular Therapeutics (FDMT) stake by 3.5% in Q1 2026, selling an estimated $1.5K and leaving 4,806 shares worth $44.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3897.

Carson Wealth (CWM LLC) first reported a position in FDMT in Q1 2022 and has held it in 9 quarters since. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

Carson Wealth (CWM LLC) held 4,806 shares of 4D Molecular Therapeutics worth $44.7K as of Q1 2026.
Carson Wealth (CWM LLC) sold 172 4D Molecular Therapeutics shares in Q1 2026, an estimated $1.5K.
4D Molecular Therapeutics made up ﹤0.01% of Carson Wealth (CWM LLC)'s portfolio in Q1 2026, its #3897 holding.
Carson Wealth (CWM LLC) first reported a position in 4D Molecular Therapeutics in Q1 2022 and has held it in 9 quarters since.
152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Carson Wealth (CWM LLC)'s 13F filing for Q1 2026, filed 14 May 2026.